COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)

COURSEWORK REQUIREMENTS REPORT*

* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details. See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.

Jennifer Dzigiel (ID: 2614710) · Name:

· Email: jennifer.dzigiel@rapidmedicalresearch.com

· Institution Affiliation: Quorum Review (ID: 620) • Institution Unit: Clinical Study Coordinator

216-682-0320 · Phone:

• Curriculum Group: **CITI Good Clinical Practice** · Course Learner Group: CITI Good Clinical Practice Course

Stage 1 - GCP · Stage:

This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site · Description:

Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of

GCP training among trial sponsors.

· Report ID: 17582237 01/08/2016 Completion Date: • Expiration Date: 01/07/2017 • Minimum Passing: 80 · Reported Score*: 96

REQUIRED AND ELECTIVE MODULES ONLY	DATE COMPLETED	SCORE
The CITI Good Clinical Practice Course for Clinical Trials Involving Drugs and Devices (ID: 1350)	01/08/16	3/3 (100%)
Overview of New Drug Development (ID: 1351)	01/08/16	4/5 (80%)
Overview of ICH GCP (ID: 1352)	01/08/16	4/4 (100%)
ICH - Comparison Between ICH GCP E6 and U.S. FDA Regulations (ID: 1354)	01/08/16	4/4 (100%)
Conducting Investigator-Initiated Studies According to FDA Regulations and GCP (ID; 1355)	01/08/16	3/3 (100%)
Investigator Obligations in FDA-Regulated Research (ID: 1356)	01/08/16	5/5 (100%)
Managing Investigational Agents According to GCP Requirements (ID: 1357)	01/08/16	4/5 (80%)
Overview of U.S. FDA Regulations for Medical Devices (ID: 1358)	01/08/16	3/3 (100%)
Informed Consent in Clinical Trials of Drugs, Biologics, and Devices (ID: 1359)	01/08/16	4/4 (100%)
Detecting and Evaluating Adverse Events (ID: 1360)	01/08/16	4/4 (100%)
Reporting Serious Adverse Events (ID: 1361)	01/08/16	4/4 (100%)
Audits and Inspections of Clinical Trials (ID: 1363)	01/08/16	5/5 (100%)
Monitoring of Clinical Trials by Industry Sponsors (ID: 1362)	01/08/16	5/5 (100%)
Completing the CITI GCP Course (ID: 1364)	01/08/16	No Quiz
Quorum Review IRB (ID: 929)	01/08/16	No Quiz

For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution identified above or have been a paid Independent Learner.

CITI Program Email: citisupport@miami.edu Phone: 305-243-7970

Web: https://www.citiprogram.org

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)

COURSEWORK TRANSCRIPT REPORT**

** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.

• Name: Jennifer Dzigiel (ID: 2614710)

Email: jennifer.dzigiel@rapidmedicalresearch.com

• Institution Affiliation: Quorum Review (ID: 620)
• Institution Unit: Clinical Study Coordinator

• Phone: 216-682-0320

• Curriculum Group: CITI Good Clinical Practice
• Course Learner Group: CITI Good Clinical Practice Course

• Stage: Stage 1 - GCP

• Description: This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site

Personnel Training Identified by TransCelerate BioPharma as necessary to enable mutual recognition of

GCP training among trial sponsors.

• Report ID: 17582237
• Report Date: 01/08/2016
• Current Score**: 98

REQUIRED, ELECTIVE, AND SUPPLEMENTAL MODULES	MOST RECENT	SCORE
The CiTI Good Clinical Practice Course for Clinical Trials Involving Drugs and Devices (ID: 1350)	01/08/16	3/3 (100%)
Overview of New Drug Development (ID: 1351)	01/08/16	4/5 (80%)
Overview of ICH GCP (ID: 1352)	01/08/16	4/4 (100%)
ICH - Comparison Between ICH GCP E6 and U.S. FDA Regulations (ID: 1354)	01/08/16	4/4 (100%)
Conducting Investigator-Initiated Studies According to FDA Regulations and GCP (ID: 1355)	01/08/16	3/3 (100%)
Investigator Obligations in FDA-Regulated Research (ID: 1356)	01/08/16	5/5 (100%)
Managing Investigational Agents According to GCP Requirements (ID: 1357)	01/08/16	5/5 (100%)
Overview of U.S. FDA Regulations for Medical Devices (ID: 1358)	01/08/16	3/3 (100%)
Informed Consent in Clinical Trials of Drugs, Biologics, and Devices (ID: 1359)	01/08/16	4/4 (100%)
Detecting and Evaluating Adverse Events (ID: 1360)	01/08/16	4/4 (100%)
Reporting Serious Adverse Events (ID: 1361)	01/08/16	4/4 (100%)
Audits and Inspections of Clinical Trials (ID: 1363)	01/08/16	5/5 (100%)
Monitoring of Clinical Trials by Industry Sponsors (ID: 1362)	01/08/16	5/5 (100%)
Completing the CITI GCP Course (ID: 1364)	01/08/16	No Quiz
Quorum Review IRB (ID: 929)	01/08/16	No Quiz

For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution identified above or have been a paid independent Learner.

CITI Program

Email: citisupport@miami.edu Phone: 305-243-7970

Web: https://www.citiprogram.org

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) COURSEWORK TRANSCRIPT REPORT**

** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.

• Name: Jennifer Dzigiel (ID: 2614710)

Email: jennifer.dzigiel@rapidmedicalresearch.com

Institution Affiliation: Quorum Review (ID: 620)
 Institution Unit: Clinical Study Coordinator

• Phone: 216-682-0320

• Curriculum Group: CITI Health Information Privacy and Security (HIPS)

· Course Learner Group: CITI Health Information Privacy and Security (HIPS) for All Researchers

• Stage: Stage 1 - HIPS

• Report ID: 17582238
• Report Date: 01/08/2016
• Current Score**: 90

REQUIRED, ELECTIVE, AND SUPPLEMENTAL MODULES	MOST RECENT	SCORE
Basics of Health Privacy (ID: 1417)	01/08/16	15/16 (94%)
Health Privacy Issues for Researchers (ID: 1419)	01/08/16	4/5 (80%)
Quorum Review IRB (ID: 929)	01/08/16	No Quiz

For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution identified above or have been a paid independent Learner.

CITI Program

Email: citisupport@miami.edu Phone: 305-243-7970

Web: https://www.citiprogram.org

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)

COURSEWORK REQUIREMENTS REPORT*

* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details, See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.

• Name: Jennifer Dzigiel (ID: 2614710)

• Email: jennifer.dzigiel@rapidmedicalresearch.com

Institution Affiliation: Quorum Review (ID: 620)
 Institution Unit: Clinical Study Coordinator

• Phone: 216-682-0320

Curriculum Group: CITI Health Information Privacy and Security (HIPS)

· Course Learner Group: CITI Health Information Privacy and Security (HIPS) for All Researchers

Stage: Stage 1 - HIPS

Report ID: 17582238
 Completion Date: 01/08/2016
 Expiration Date: 01/07/2017
 Minimum Passing: 80
 Reported Score*: 81

REQUIRED AND ELECTIVE MODULES ONLY	DATE COMPLETED	SCORE
Basics of Health Privacy (ID: 1417)	01/08/16	15/16 (94%)
Health Privacy Issues for Researchers (ID: 1419)	01/08/16	2/5 (40%)
Quorum Review IRB (ID: 929)	01/08/16	No Quiz

For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing Institution identified above or have been a paid Independent Learner.

CITI Program

Email: <u>citisupport@miami.edu</u> Phone: 305-243-7970 Web: <u>https://www.citiprogram.org</u>